Market closedNon-fractional
Aldeyra Therapeutics/ALDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Aldeyra Therapeutics
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Ticker
ALDX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Lexington, United States
Employees
10
Website
www.aldeyra.com
ALDX Metrics
BasicAdvanced
$190M
Market cap
-
P/E ratio
-$0.51
EPS
1.44
Beta
-
Dividend rate
Price and volume
Market cap
$190M
Beta
1.44
Financial strength
Current ratio
6.498
Quick ratio
3.831
Long term debt to equity
0.182
Total debt to equity
13.805
Interest coverage (TTM)
-17.02%
Management effectiveness
Return on assets (TTM)
-14.29%
Return on equity (TTM)
-23.94%
Valuation
Price to book
1.68
Price to tangible book (TTM)
1.68
Price to free cash flow (TTM)
-6.11
Growth
Earnings per share change (TTM)
-51.16%
3-year earnings per share growth
-20.84%
What the Analysts think about ALDX
Analyst Ratings
Majority rating from 8 analysts.
ALDX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8M
70.21%
Profit margin
0.00%
NaN%
ALDX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.15
-$0.14
-$0.08
-$0.14
-
Expected
-$0.31
-$0.24
-$0.14
-$0.11
-$0.15
Surprise
-51.75%
-41.28%
-42.96%
26.55%
-
ALDX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aldeyra Therapeutics stock?
Aldeyra Therapeutics (ALDX) has a market cap of $190M as of July 06, 2024.
What is the P/E ratio for Aldeyra Therapeutics stock?
The price to earnings (P/E) ratio for Aldeyra Therapeutics (ALDX) stock is 0 as of July 06, 2024.
Does Aldeyra Therapeutics stock pay dividends?
No, Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Aldeyra Therapeutics dividend payment date?
Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Aldeyra Therapeutics?
Aldeyra Therapeutics (ALDX) has a beta rating of 1.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Aldeyra Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.